Related Experiment Video
Updated: Dec 31, 2025
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
Published on: October 10, 2025
Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models
Hideyuki Matsushima1, Masaki Kaibori1, Masahiko Hatta1
1Department of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
Background:
Few chemotherapies are available for neuroendocrine tumors, especially for highly malignant neuroendocrine cancers. The third-generation oncolytic herpes simplex virus type 1 (HSV-1) T-01 selectively replicates in tumor cells and shows cytotoxicity against tumor cells without damaging surrounding normal tissues. We examined the antitumor effect of T-01 to explore novel treatments for patients with neuroendocrine tumors.
Methods:
The cytotoxicity of T-01 was tested in two human and one murine neuroendocrine tumor cell lines in vitro. Mouse models with subcutaneously implanted human neuroendocrine tumor QGP1 cells were used to investigate T-01 efficacy in vivo.
Results:
T-01 showed cytotoxicity against the three cell lines in vitro. In xenograft models, the growth of tumors derived from QGP1 cells was inhibited by T-01 compared with control group. Although weight loss of mice was observed with tumor growth in the control group, it was suppressed by T-01 administration. The antitumor effects of T-01 were dependent on virus concentration and frequency of administration.
Conclusions:
T-01 effectively inhibits tumor cell proliferation in a poorly differentiated NEC mouse model. These results suggest that the third-generation oncolytic HSV-1 may serve as a novel treatment for patients with neuroendocrine tumors.
Insights
The oncolytic herpes simplex virus type 1 (HSV-1) T-01 demonstrated significant antitumor effects against neuroendocrine tumors in preclinical models. This novel therapy effectively inhibited tumor growth and improved mouse weight, suggesting potential for treating neuroendocrine cancers.
Area of Science:
- Oncology
- Virology
- Cancer Therapeutics
Background:
- Limited effective chemotherapies exist for neuroendocrine tumors (NETs), particularly high-grade variants.
- Oncolytic herpes simplex virus type 1 (HSV-1) T-01 selectively targets and destroys tumor cells while sparing healthy tissue.
Purpose of the Study:
- To evaluate the antitumor efficacy of the novel oncolytic HSV-1 T-01 in neuroendocrine tumors.
- To explore T-01 as a potential new therapeutic strategy for NET patients.
Main Methods:
- In vitro cytotoxicity assays were performed on human and murine NET cell lines.
- In vivo efficacy was assessed using mouse xenograft models implanted with human NET QGP1 cells.
Main Results:
- T-01 exhibited significant cytotoxicity against all tested NET cell lines in vitro.
- T-01 administration suppressed tumor growth in vivo and prevented weight loss in tumor-bearing mice.
- Antitumor effects were dose- and frequency-dependent.
Conclusions:
- Oncolytic HSV-1 T-01 demonstrated potent antitumor activity in a poorly differentiated neuroendocrine carcinoma mouse model.
- These findings support the potential of T-01 as a novel therapeutic agent for neuroendocrine tumors.
More Related Videos
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
07:10Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
Published on: March 7, 2011